250 related articles for article (PubMed ID: 37380741)
1. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
4. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer.
Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q
Front Immunol; 2023; 14():1066527. PubMed ID: 36825006
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread Across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy, and Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Tian Y; Shi Z; Wang C; Ke S; Qiu H; Zhao W; Wu Y; Chen J; Zhang Y; Chen Y
Ann Surg Oncol; 2024 Feb; 31(2):860-871. PubMed ID: 37947979
[TBL] [Abstract][Full Text] [Related]
8. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
9. Reliability and safety of minimally invasive esophagectomy after neoadjuvant chemoradiation: a retrospective study.
Liu G; Han Y; Peng L; Wang K; Fan Y
J Cardiothorac Surg; 2019 May; 14(1):97. PubMed ID: 31138245
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
11. Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.
Chen D; Wang W; Mo J; Ren Q; Miao H; Chen Y; Wen Z
BMC Cancer; 2021 Feb; 21(1):145. PubMed ID: 33563244
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in locally advanced esophageal cancer: An updated meta-analysis.
Liang Z; Chen T; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Jan; 103(3):e36785. PubMed ID: 38241577
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
[TBL] [Abstract][Full Text] [Related]
14. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.
Hong ZN; Gao L; Weng K; Huang Z; Han W; Kang M
Front Immunol; 2022; 13():836338. PubMed ID: 35300335
[TBL] [Abstract][Full Text] [Related]
15. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Xu L; Wei XF; Li CJ; Yang ZY; Yu YK; Li HM; Xie HN; Yang YF; Jing WW; Wang Z; Kang XZ; Zhang RX; Qin JJ; Xue LY; Bi N; Chen XK; Li Y
Front Immunol; 2022; 13():1052542. PubMed ID: 36466925
[TBL] [Abstract][Full Text] [Related]
16. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X
BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial.
Wang YJ; Li KK; Xie XF; Bao T; Hao ZP; Long J; Wang S; Zhong ZY; Guo W
Front Oncol; 2022; 12():908841. PubMed ID: 35982957
[TBL] [Abstract][Full Text] [Related]
19. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma.
Chen HS; Lin CH; Wu SC; Wang BY
Ann Surg Oncol; 2022 Jun; 29(6):3617-3627. PubMed ID: 34994899
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
